Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpiCeram vs Aveeno in Atopic Dermatitis
NCT03663673Phase 1Completed
- Sponsor
- Stanford University
- Start
- Sep 2018
- Primary completion
- Jul 2019
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EpiCeram in atopic dermatitis (AD), sponsored by Stanford University. Primary endpoint: Skin barrier function assessed by Transepidermal Water Loss Area Under the Curve at 2 weeks. Started Sep 2018; status: completed.
02
Drugs
EpiCeram
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03663673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03663673.